DXC Technology Lifts FY21 EPS Outlook, But Cuts Revenue Guidance

DXC Technology Company (DXC) Wednesday revised its full-year outlook. The company increased its adjusted earnings guidance, but lowered its revenue guidance range due to foreign exchange fluctuations.

The company now expects adjusted earnings of $3.52 to $3.72 per share and revenues of $16.4 billion to $16.6 billion

Previously, the company expected adjusted earnings of $3.45 to $3.65 per share and revenues of $16.6 billion to $16.8 billion.

Analysts polled by Thomson Reuters currently estimate earnings of $3.59 per share on revenues of $16.76 billion.

CFO Ken Sharp said, "The second quarter of fiscal year 2022 saw continued progress toward building our strong financial foundation for DXC. Our recent refinancing extends debt maturities, lowers maturity towers, and reduces ongoing interest expense by approximately $50 million annually. We continue to significantly reduce restructuring and TSI expense, lower capital lease payments, reduce our facility footprint and drive our ongoing cost optimization program. Taken together, these initiatives are driving an improvement in DXC's free cash flow generation capability."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
IBSA Pharma Inc. is recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level due to subpotency, the U.S. Food and Drug Administration said. TIROSINT-SOL is indicated for Hypothyroidism and Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression. Meanwhile, the recall does not apply to TIROSINT (levothyroxine sodium) capsules. The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval. German banking major Deutsche Bank AG reported Thursday a significantly higher profit in its fourth quarter and fiscal 2022, mainly reflecting a tax benefit in the U.S, despite weakness in Investment Bank and asset management revenues. The company said it recorded its highest annual profit, both before and after tax, since 2007. However, Deutsche Bank shares were losing around 4 percent...
Follow RTT